Can the integration of blood-based biomarkers into Alzheimer’s disease diagnosis revolutionize the field?
The authors critically appraise the current evidence supporting plasma phosphorylated tau at threonine 217 (p-tau217) as the leading BBM for AD, and highlight current limitations, unresolved challenges, and future perspectives for the integration of plasma biomarkers into routine clinical practice.